Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poland’s Mabion Gets €30m R&D Loan

Hopes To Be Among The First EU Firms With Biosimilar Rituximab

Executive Summary

After receiving a €30m loan from the European Investment Bank, Mabion believes it could be among the first EU-based companies to introduce biosimilar rituximab into the European market.

You may also be interested in...



Amgen Gets US Infliximab Nod

Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.

US Generics Market Continues To Seek Stability

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

AAM Welcomes Potential USMCA Revision

The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.

Topics

UsernamePublicRestriction

Register

GB149300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel